Patient must meet ALL of the following criteria:

- □ Yes  □ No  **Positive test for SARS-CoV-2**
- □ Yes  □ No  Onset of symptoms within past 7 days
- □ Yes  □ No  ≥12 years of age and < 22 years of age*
- □ Yes  □ No  Weight ≥ 40 kg
- □ Yes  □ No  Patient is not requiring supplemental oxygen
- □ Yes  □ No  No increase in baseline oxygen requirement for patients on baseline O2 from a non-COVID-19 comorbidity
- □ Yes  □ No  No prior administration of REGEN-COV, bamlanivimab/etesevimab or sotrovimab within the last 6 months

*Eligible ages include those between the ages of 12 – 21 years and 364 days, with exceptions for young adult patients > 22 years who are known to Dayton Children’s specialist teams

DIAGNOSTIC CRITERIA

**Patient must meet ONE of the following criteria**

- □ BMI ≥ 85th percentile for ages 12-17 years or ≥ 35 for those ≥18 years
- □ Chronic Kidney Disease
- □ Diabetes
- □ Immunosuppressive Disease
- □ Currently on immunosuppressive treatment
- □ Sickle Cell Disease
- □ Congenital or acquired heart disease
- □ Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity
- □ Medical-related technological dependence (tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19))
- □ Severe asthma (requiring injectable biologic therapies) or other chronic respiratory disease

[Bebe]telovimab 175 mg IV push over at least 30 seconds once followed by one-hour observation period